Farzin Haque
Stock Analyst at Jefferies
(2.92)
# 2,778
Out of 4,835 analysts
12
Total ratings
63.6%
Success rate
12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Farzin Haque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Reiterated: Buy | $50 → $48 | $22.30 | +115.25% | 2 | Sep 9, 2026 | |
| RLMD Relmada Therapeutics | Initiated Coverage: Buy | $9 | $4.52 | +99.12% | 1 | Dec 21, 2025 | |
| VERA Vera Therapeutics | Reiterated: Buy | $57 → $45 | $35.05 | +28.39% | 4 | Nov 26, 2025 | |
| RIGL Rigel Pharmaceuticals | Upgraded: Buy | $42 | $47.24 | -11.09% | 1 | Nov 5, 2025 | |
| NUVB Nuvation Bio | Initiated Coverage: Buy | $10 | $6.07 | +64.74% | 1 | Sep 29, 2025 | |
| HOWL Werewolf Therapeutics | Initiated Coverage: Buy | $4 | $0.982 | n/a | 1 | Aug 4, 2025 | |
| PYXS Pyxis Oncology | Reiterated: Buy | $10 → $6 | $3.21 | n/a | 2 | Mar 18, 2025 |
Vor Biopharma
Sep 9, 2026
Reiterated: Buy
Price Target: $50 → $48
Current: $22.30
Upside: +115.25%
Relmada Therapeutics
Dec 21, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $4.52
Upside: +99.12%
Vera Therapeutics
Nov 26, 2025
Reiterated: Buy
Price Target: $57 → $45
Current: $35.05
Upside: +28.39%
Rigel Pharmaceuticals
Nov 5, 2025
Upgraded: Buy
Price Target: $42
Current: $47.24
Upside: -11.09%
Nuvation Bio
Sep 29, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $6.07
Upside: +64.74%
Werewolf Therapeutics
Aug 4, 2025
Initiated Coverage: Buy
Price Target: $4
Current: $0.982
Upside: n/a
Pyxis Oncology
Mar 18, 2025
Reiterated: Buy
Price Target: $10 → $6
Current: $3.21
Upside: n/a